Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage

Transplantation

Volumn 96, Issue 5, 2013, Pages 445-453

  Kuraya, Daisuke ^a   Watanabe, Masaaki ^a   Koshizuka, Yasuyuki ^a   Ogura, Masaomi ^a   Yoshida, Tadashi ^a   Asahi, Yoh ^a   Kamachi, Hirofumi ^a   Nakamura, Takashi ^b   Harashima, Hideyoshi ^b   Ozaki, Michitaka ^a   Umezawa, Kazuo ^c   Matsushita, Michiaki ^a   Yamashita, Kenichiro ^a   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

DHMEQ; Early graft loss; Nuclear factor JB; Pancreatic islet transplantation

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFICACY; GRAFT RECIPIENT; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATION; ISOGRAFT; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; BENZAMIDES; CYCLOHEXANONES; DIABETES MELLITUS, EXPERIMENTAL; HMGB1 PROTEIN; ISLETS OF LANGERHANS TRANSPLANTATION; LIPOSOMES; MACROPHAGE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; POSTOPERATIVE COMPLICATIONS; STREPTOZOCIN;

EID: 84883550951     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829b0744     Document Type: Article

References (49)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230
2. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039
3. Contreras JL, Eckstein C, Smyth CA, et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004; 53: 2804
4. Yin D, Ding JW, Shen J, et al. Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant 2006; 6: 60
5. Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48: 1907
6. Titus TT, Horton PJ, Badet L, et al. Adverse outcome of human isletallogeneic blood interaction. Transplantation 2003; 75: 1317
7. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755
8. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51: 55
9. Satoh M, Yasunami Y, Matsuoka N, et al. Successful islet transplantation to two recipients from a single donor by targeting proinflammatory cytokines in mice. Transplantation 2007; 83: 1085
10. Matsuoka N, Itoh T, Watarai H, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010; 120: 735
11. Moberg L, Korsgren O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol 2005; 142: 125 12. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51: 1779
12. CuiW,Wilson JT,Wen J, et al. Thrombomodulin improves early outcomes after intraportal islet transplantation. Am J Transplant 2009; 9: 1308
13. Clayton HA, Davies JE, Sutton CD, et al. A coculture model of intrahepatic islet transplantation: activation of Kupffer cells by islets and acinar tissue. Cell Transplant 2001; 10: 101
14. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol 2005; 77: 587
15. Bottino R, Fernandez LA, Ricordi C, et al. Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes 1998; 47: 316
16. Arnush M, Heitmeier MR, Scarim AL, et al. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998; 102: 516
17. Heitmeier MR, Scarim AL, Corbett JA. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitricoxide synthase expression induced by interleukin 1. J Biol Chem 1997; 272: 13697
18. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7: 758
19. Zhang L, Ding X, Cui J, et al. Cysteine methylation disrupts ubiquitinchain sensing in NF-kappaB activation. Nature 2011; 481: 204
20. Hayden MS,West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758
21. Lawrence T, Bebien M, Liu GY, et al. IKKalpha limits macrophage NFkappaB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138
22. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749
23. Takahashi T, Matsumoto S, Matsushita M, et al. Donor pretreatment with DHMEQ improves islet transplantation. J Surg Res 2010; 163: e23
24. Matsumoto N, Ariga A, To-e S, et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10: 865
25. Ariga A, Namekawa J, Matsumoto N, et al. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappaB by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625
26. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331
27. Steer SA, Scarim AL, Chambers KT, et al. Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med 2006; 3: e17
28. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin proteinHMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191
29. Yamamoto M, Horie R, Takeiri M, et al. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008; 51: 5780
30. Suzuki T, Yamashita K, Jomen W, et al. The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. J Surg Res 2008; 149: 69
31. Wakamatsu K, Nanki T, Miyasaka N, et al. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005; 7: R1348
32. Cardile V, LibraM, Caggia S, et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injuryinduced by interferon-gamma and histamine in NCTC 2544 keratinocytes. Clin Exp Pharmacol Physiol 2010; 37: 679
33. Kubota T, Hoshino M, Aoki K, et al. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res Ther 2007; 9: R97
34. Iwata D, Kitaichi N, Miyazaki A, et al. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-kappaB Inhibitor dehydroxy methyl epoxyquinomicin in mice. Invest Ophthalmol Vis Sci 2010; 51: 2077
35. Funakoshi T, Yamashita K, Ichikawa N, et al. A novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. J Crohns Colitis 2012; 6: 215
36. Saisho Y, Hirose H, Horimai C, et al. Effects of DHMEQ, a novel nuclear factor-kappaB inhibitor, on beta cell dysfunction in INS-1 cells. Endocr J 2008; 55: 433
37. Saldeen J. Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells. Endocrinology 2000; 141: 2003
38. Gao Q, Ma LL, Gao X, et al. TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant 2010; 10: 1588
39. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506
40. Palumbo R, Galvez BG, Pusterla T, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NFkappaB activation. J Cell Biol 2007; 179: 33
41. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35
42. Suzuki E, Sugiyama C, Umezawa K. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. Biomed Pharmacother 2009; 63: 351
43. Suzuki E, Umezawa K. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother 2006; 60: 578
44. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008; 112: 935
45. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28: 477
46. Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011; 2011: 727241
47. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007; 7: 964
48. Suzuki Y, Sugiyama C, Ohno O, et al. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-JB inhibitor. Tetrahedron 2004; 60: 7061
49. Yamada S, Yakabe K, Ishii J, et al. New high mobility group box 1 assay system. Clin Chim Acta 2006; 372: 173.